How Do MSA Bladder and Blood Pressure Meds Interact?
At a Glance
In Multiple System Atrophy (MSA), bladder medications can dangerously lower blood pressure, while blood pressure pills can make it harder to empty your bladder. Specialists manage this tug-of-war using lifestyle changes, carefully selected alternative drugs, and sometimes catheterization.
Treating both bladder problems and blood pressure drops (neurogenic orthostatic hypotension, or nOH) at the same time in Multiple System Atrophy (MSA) is difficult because the medications used for one condition often actively worsen the other. This creates a “tug-of-war” where treatments for your bladder can cause your blood pressure to drop dangerously low, while treatments designed to raise your blood pressure can make it much harder to empty your bladder. [1][2]
The Medication “Tug-of-War”
In MSA, the autonomic nervous system—which controls automatic functions like blood pressure and bladder function—begins to fail. [3] When specialists try to use medications to fix these issues, they often run into competing effects.
How Bladder Medications Lower Blood Pressure
If you are struggling to empty your bladder, doctors often prescribe alpha-blockers (such as tamsulosin). These medications work by relaxing the muscles in the bladder neck and prostate, making it easier for urine to flow. However, these same medications also relax the blood vessels throughout your body. [1][4] In someone with MSA whose blood pressure already drops when standing up, relaxing the blood vessels further can severely worsen orthostatic hypotension, increasing the risk of dizziness and fainting. [1][4]
Other common bladder medications are anticholinergics, which are used to calm an overactive bladder to reduce urgency and leakage. Unfortunately, these drugs increase the risk of urinary retention (the inability to empty the bladder entirely) and can cause confusion or memory problems in people with MSA. [5][6] It is important to know that these cognitive issues are typically side effects of the drug and not a permanent decline; they usually improve if the medication is stopped.
How Blood Pressure Medications Worsen Bladder Retention
To treat nOH and prevent fainting, doctors often prescribe pressor agents (like midodrine or droxidopa). These medications are alpha-1 adrenoceptor agonists, meaning they work by constricting (tightening) blood vessels to push blood up to your brain and raise your blood pressure. [7] However, this tightening effect also affects the muscles around the bladder neck. [8] For an MSA patient who already has trouble emptying their bladder, this added resistance can worsen urinary retention and increase the amount of urine left in the bladder after going to the bathroom (post-void residual volume). [8] Leaving urine in the bladder increases the risk of urinary tract infections, which can severely aggravate all other MSA symptoms.
Furthermore, medications that raise blood pressure carry a significant risk of supine hypertension—dangerously high blood pressure when you are lying flat. [9][7] Because of this, patients taking pressor agents must be very careful not to lie completely flat, especially at night. [4][10]
How Specialists Balance the Competing Needs
Because of this direct clash, managing these symptoms requires a careful, personalized approach, usually involving coordination between a neurologist and a urologist. [11][12] Specialists manage this balance through several strategies:
- Prioritizing Non-Drug Treatments: Before increasing medication doses, your care team will likely emphasize lifestyle strategies. Using compression garments (like abdominal binders), managing fluid and salt intake, elevating the head of your bed, and strategically timing when you drink fluids or take medications can help control blood pressure without affecting your bladder. [1][13]
- Alternative Bladder Medications: Instead of anticholinergics, doctors may try beta-3 agonists (like mirabegron) to treat overactive bladder. These are often better tolerated by patients with autonomic failure, though they still require careful monitoring because they can affect blood pressure and heart rate. [14][4]
- Catheterization: If medications to raise blood pressure are causing severe urinary retention, or if alpha-blockers are causing dangerous blood pressure drops, the safest option for the bladder may be clean intermittent catheterization (CIC). This involves inserting a thin tube to drain the bladder at regular intervals, bypassing the need for medications that relax the bladder neck. [8] While it sounds intimidating, patients and caregivers can be easily trained to do this at home, and it quickly becomes a common, manageable daily routine.
- Urodynamic Testing: To know exactly what is happening in the bladder, urologists often perform urodynamic testing. This helps ensure that the chosen treatment targets the specific type of dysfunction without causing unnecessary side effects elsewhere. [1]
Common questions in this guide
Why do my bladder medications make my blood pressure drop?
Do blood pressure medications affect bladder control in MSA?
Are there bladder medications that won't affect my memory or blood pressure?
What is the safest way to empty my bladder if medications cause side effects?
What is supine hypertension and how is it related to MSA medications?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Are any of the medications I am currently taking for my bladder contributing to my blood pressure drops?
- 2.If we start a medication for my blood pressure, how will we monitor its effect on my ability to empty my bladder?
- 3.Would a beta-3 agonist like mirabegron be a safer option for my overactive bladder symptoms than my current medication?
- 4.Should we consider intermittent catheterization instead of using medications that might lower my blood pressure or cause confusion?
- 5.Am I at risk for supine hypertension with my current blood pressure medications, and what should my sleeping position be?
- 6.Can you coordinate with my urologist/neurologist so we can find a treatment plan that balances both sets of symptoms?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study.
Eschlböck S, Kiss G, Krismer F, et al.
Movement disorders clinical practice 2021; (8(7)):1052-1060 doi:10.1002/mdc3.13307.
PMID: 34631941 - 2
Urodynamic and gait analyses in multiple system atrophy.
Tsuchiya A, Terayama K, Sakakibara R, et al.
Journal of the neurological sciences 2020; (411()):116676 doi:10.1016/j.jns.2020.116676.
PMID: 32001376 - 3
A historical review of multiple system atrophy with a critical appraisal of cellular and animal models.
Marmion DJ, Peelaerts W, Kordower JH
Journal of neural transmission (Vienna, Austria : 1996) 2021; (128(10)):1507-1527 doi:10.1007/s00702-021-02419-8.
PMID: 34613484 - 4
Symptomatic therapy of multiple system atrophy.
Rohrer G, Höglinger GU, Levin J
Autonomic neuroscience : basic & clinical 2018; (211()):26-30 doi:10.1016/j.autneu.2017.10.006.
PMID: 29104019 - 5
Cognitive and Autonomic Dysfunction in Multiple System Atrophy Type P and C: A Comparative Study.
Lazzeri G, Franco G, Difonzo T, et al.
Frontiers in neurology 2022; (13()):912820 doi:10.3389/fneur.2022.912820.
PMID: 35785342 - 6
Psychiatric Manifestations of Neurological Diseases: A Narrative Review.
Maristany AJ, Sa BC, Murray C, et al.
Cureus 2024; (16(7)):e64152 doi:10.7759/cureus.64152.
PMID: 39119372 - 7
Supine hypertension in Parkinson's disease and multiple system atrophy.
Fanciulli A, Göbel G, Ndayisaba JP, et al.
Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2016; (26(2)):97-105 doi:10.1007/s10286-015-0336-4.
PMID: 26801189 - 8
Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy.
Ogawa T, Sakakibara R, Kuno S, et al.
Nature reviews. Urology 2017; (14(2)):79-89 doi:10.1038/nrurol.2016.254.
PMID: 27958390 - 9
Prevalence of Supine Hypertension in Alpha-Synucleinopathies: A Systematic Review and Meta-Analysis.
Moss Lopes PR, Westphal Filho FL, Mendes Filho FSM, et al.
Movement disorders clinical practice 2025; (12(11)):1703-1713 doi:10.1002/mdc3.70142.
PMID: 40406920 - 10
Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism.
Giagkou N, Stamelou M
CNS drugs 2018; (32(9)):827-837 doi:10.1007/s40263-018-0551-3.
PMID: 30051337 - 11
A strategic approach of the management of sleep-disordered breathing in multiple system atrophy.
Laga A, Bauters F, Hertegonne K, et al.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2025; (21(4)):703-711 doi:10.5664/jcsm.11472.
PMID: 39539061 - 12
An overview of the current management and emerging therapies of Multiple system atrophy.
Sorrentino C, Baldelli L, Calandra-Buonaura G, Pellecchia MT
Expert review of neurotherapeutics 2026; (26(3)):279-300 doi:10.1080/14737175.2025.2605711.
PMID: 41504651 - 13
Diagnostic symptoms, treatment patterns, and healthcare resource utilization in multiple system atrophy in the United States.
Kaplan S, Xie H, Kumar A
Neurodegenerative disease management 2026; (16(2)):143-152 doi:10.1080/17582024.2025.2554490.
PMID: 40916472 - 14
Multiple system atrophy related neurogenic bladder: mechanism and treatment.
Ren G, Wang Y, Tian H, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(5)):1965-1976 doi:10.1007/s10072-025-08002-3.
PMID: 39875674
This page explains MSA medication interactions for educational purposes only. Always consult your neurologist and urologist before starting, stopping, or changing any blood pressure or bladder medications.
Get notified when new evidence is published on Multiple system atrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.